nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection

RxCUI: 2596778
RxNorm name: nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection
Display name: nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection
Full name: nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:39:16

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761234	Opdualag	nivolumab and relatlimab-rmbw	351(a)	Rx	2026-07-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
OPDUALAG	NIVOLUMAB AND RELATLIMAB-RMBW	E.R. Squibb & Sons, L.L.C.	b22c9d83-3256-4e17-85f7-f331a504adc6	2026-06-08	Warnings, Adverse reactions	Exact identifier rxcui: 2596778

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
b22c9d83-3256-4e17-85f7-f331a504adc6	nivolumab-relatlimab-rmbw 240 MG / 80 MG in 20 ML Injection [PSN] · 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection [SCD] · nivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection [SY]	3	2	These highlights do not include all the information needed to use OPDUALAG safely and effectively. See full prescribing information for OPDUALAG. OPDUALAG™ (nivolumab and relatlimab-rmbw) injection, for intravenous use Initial U.S. Approval: 2022	20240301